HOLLOW-FIBER DEVICE FOR REMOVING IL-1 IN HEMATOPOIESIS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13920
Amount: $498,012.00
Phase: Phase II
Program: SBIR
Awards Year: 1992
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Bend Research Inc.
64550 Research Rd, Bend, OR, 97701
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Paul Van Eikeren
 (503) 382-4100
Business Contact
Phone: () -
Research Institution
N/A
Abstract
ONE GOAL OF MEDICAL RESEARCH ON HEMATOPOIESIS-THE GROWTH AND DIFFERENTIATION OF PLURIPOTENT STEM CELLS WITHIN THE BONE MARROW-IS TO DUPLICATE THAT PROCESS IN VITRO FOR TREATMENT OF DISEASE. CURRENT METHODS ARE PLAGUED BY THE INHERENT COMPLEXITY OF THE PROCESS; FOR EXAMPLE, THE SAME GROWTH FACTORS THAT STIMULATE STEM-CELL GROWTH CAN ALSO STIMULATE UNWANTED DIFFERENTIATION. A METHOD THAT COULD REMOVE AND REPLACE SELECTED GROWTH FACTORS WOULD BE INVALUABLE TO THE PRACTICAL USE OF IN VITRO HEMATOPOIESIS. BEND RESEARCH, INC., PLANS TO DEVELOP A HOLLOW-FIBER MEMBRANE ADSORBENT (HFMA) THAT SELECTIVELY REMOVES HEMATOPOIETIC GROWTH FACTORS. IN PHASE I, THE FEASIBILITY OF THE CONCEPT WILL BE TESTED BY REMOVING INTERLEUKIN-1 (IL-1) FROM STEM-CELL CULTURE MEDIUM USING ANTIBODIES FOR IL-1 IMMOBILIZED IN THE PORES OF THE HOLLOW FIBERS. IN PHASE II, AN ENTIRE STEM-CELL CULTURE SYSTEM IN WHICH THE HFMAS WOULD CONTROL THE REMOVAL AND ADDITION OF SPECIFICGROWTH FACTORS WILL BE DEVELOPED. ULTIMATELY, THIS COULD LEAD TO COMMERCIALIZATION OF A SYSTEM FOR GROWING EITHER STEM CELLS OR SPECIFIC BLOOD-CELL LINEAGES FOR SUCH THERAPIES AS STEM-CELL REPLACEMENT IN CANCER TREATMENT OR TREATMENT OF IMMUNODEFICIENCY DISORDERS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government